Related Experiment Video
Updated: Jun 24, 2026

Modeling Brain Metastasis by Internal Carotid Artery Injection of Cancer Cells
Published on: August 2, 2022
Emerging drugs in metastatic breast cancer
1Hacettepe University Institute of Oncology, Department of Medical Oncology, Ankara, Turkey.
Background:
Breast cancer is the most common cancer among women and comprises 26% of all cancers diagnosed in women in the United States. Among presenting patients, 3 - 6% already have metastatic disease, and 50 - 70% of the remaining patients develop systemic relapse. Recently many new drugs, particularly molecular targeted therapies, have been developed in the field.
Objective:
To review the current and emerging data on the treatment of metastatic breast cancer, with emphasis on novel therapies that show promise.
Methods:
PubMed and ASCO annual meeting abstracts were used for a literature search.
Results/Conclusions:
Despite improved response rates, conventional treatments still result only in transient remission in most cases. New therapeutic alternatives and new strategies to overcome drug resistance are needed to improve these results.
Insights
New molecular targeted therapies offer promise for metastatic breast cancer treatment. Further research is needed to overcome drug resistance and improve patient outcomes in this common cancer.
Area of Science:
- Oncology
- Medical Therapeutics
Background:
- Breast cancer is the most prevalent cancer in women, accounting for 26% of all diagnoses in the U.S.
- Metastatic disease is present at diagnosis in 3-6% of patients, with 50-70% experiencing systemic relapse.
- Recent advancements include the development of novel molecular targeted therapies.
Purpose of the Study:
- To review current and emerging treatment data for metastatic breast cancer.
- To emphasize promising novel therapeutic strategies.
Main Methods:
- Literature search conducted using PubMed.
- ASCO (American Society of Clinical Oncology) annual meeting abstracts were reviewed.
Main Results:
- Conventional treatments demonstrate improved response rates but often yield only transient remission.
- Emerging novel therapies show promise in preliminary data.
Conclusions:
- New therapeutic alternatives are crucial for improving outcomes in metastatic breast cancer.
- Strategies to overcome drug resistance are essential for achieving durable remissions.
Related Concept Videos
Targeted Cancer Therapies
There are several types of targeted therapies against specific...
Metastasis
Epithelial-to-Mesenchymal Transition
The epithelial-to-mesenchymal transition or EMT is a developmental process commonly observed in wound healing, embryogenesis, and cancer metastasis. EMT is induced by transforming growth factor-beta (TGF-β) or receptor tyrosine kinase (RTK) ligands, which further...
Drugs that Stabilize Microtubules
Drugs that Destabilize Microtubules
Mitogens and the Cell Cycle
Treatment Resistant Cancers
